Ketorolac Tromethamine
Hip Dysplasia
University of California, Los AngelesPhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Hip Dysplasia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE University of California, Los Angeles | Phase 4 | BB |
Epinephrine University of California, Los Angeles | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University of California, Los Angeles | Phase 4 | BB |
LIDOCAINE University of California, Los Angeles | Phase 4 | BB |
Same molecule, other indications
Ketorolac Tromethamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →